secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001213900-26-025464
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers
--------------------------------------------------------------------------------

- 24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.
- No unexpected safety signals or serious immune-related adverse events observed in 25 evaluable patients.
- Investigator-initiated trial by University of Pittsburgh; full results expected at upcoming international cancer conference.
- Study evaluated LYMPHIR (denileukin diftitox-cxdl) + pembrolizumab in relapsed/refractory ovarian and endometrial cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/0001213900-26-025464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea0280663-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-025464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer